276 related articles for article (PubMed ID: 25005024)
1. Prion neuropathology follows the accumulation of alternate prion protein isoforms after infective titre has peaked.
Sandberg MK; Al-Doujaily H; Sharps B; De Oliveira MW; Schmidt C; Richard-Londt A; Lyall S; Linehan JM; Brandner S; Wadsworth JD; Clarke AR; Collinge J
Nat Commun; 2014 Jul; 5():4347. PubMed ID: 25005024
[TBL] [Abstract][Full Text] [Related]
2. Prion propagation and toxicity in vivo occur in two distinct mechanistic phases.
Sandberg MK; Al-Doujaily H; Sharps B; Clarke AR; Collinge J
Nature; 2011 Feb; 470(7335):540-2. PubMed ID: 21350487
[TBL] [Abstract][Full Text] [Related]
3. Pathogenic mutations within the hydrophobic domain of the prion protein lead to the formation of protease-sensitive prion species with increased lethality.
Coleman BM; Harrison CF; Guo B; Masters CL; Barnham KJ; Lawson VA; Hill AF
J Virol; 2014 Mar; 88(5):2690-703. PubMed ID: 24352465
[TBL] [Abstract][Full Text] [Related]
4. Sialylation of prion protein controls the rate of prion amplification, the cross-species barrier, the ratio of PrPSc glycoform and prion infectivity.
Katorcha E; Makarava N; Savtchenko R; D'Azzo A; Baskakov IV
PLoS Pathog; 2014 Sep; 10(9):e1004366. PubMed ID: 25211026
[TBL] [Abstract][Full Text] [Related]
5. Generation of genuine prion infectivity by serial PMCA.
Weber P; Giese A; Piening N; Mitteregger G; Thomzig A; Beekes M; Kretzschmar HA
Vet Microbiol; 2007 Aug; 123(4):346-57. PubMed ID: 17493773
[TBL] [Abstract][Full Text] [Related]
6. Soluble dimeric prion protein binds PrP(Sc) in vivo and antagonizes prion disease.
Meier P; Genoud N; Prinz M; Maissen M; Rülicke T; Zurbriggen A; Raeber AJ; Aguzzi A
Cell; 2003 Apr; 113(1):49-60. PubMed ID: 12679034
[TBL] [Abstract][Full Text] [Related]
7. Molecular Mechanism of the Misfolding and Oligomerization of the Prion Protein: Current Understanding and Its Implications.
Singh J; Udgaonkar JB
Biochemistry; 2015 Jul; 54(29):4431-42. PubMed ID: 26171558
[TBL] [Abstract][Full Text] [Related]
8. Prion protein functions and dysfunction in prion diseases.
Sakudo A; Ikuta K
Curr Med Chem; 2009; 16(3):380-9. PubMed ID: 19149584
[TBL] [Abstract][Full Text] [Related]
9. Protein misfolding cyclic amplification of prions.
Saunders SE; Bartz JC; Shikiya RA
J Vis Exp; 2012 Nov; (69):. PubMed ID: 23168797
[TBL] [Abstract][Full Text] [Related]
10. [Mechanisms of prion transmission].
Sakaguchi S
Nihon Rinsho; 2007 Aug; 65(8):1391-5. PubMed ID: 17695274
[TBL] [Abstract][Full Text] [Related]
11. Protease-resistant prions selectively decrease Shadoo protein.
Watts JC; Stöhr J; Bhardwaj S; Wille H; Oehler A; Dearmond SJ; Giles K; Prusiner SB
PLoS Pathog; 2011 Nov; 7(11):e1002382. PubMed ID: 22163178
[TBL] [Abstract][Full Text] [Related]
12. A novel, drug-based, cellular assay for the activity of neurotoxic mutants of the prion protein.
Massignan T; Stewart RS; Biasini E; Solomon IH; Bonetto V; Chiesa R; Harris DA
J Biol Chem; 2010 Mar; 285(10):7752-65. PubMed ID: 19940127
[TBL] [Abstract][Full Text] [Related]
13. Evolving views in prion glycosylation: functional and pathological implications.
Ermonval M; Mouillet-Richard S; Codogno P; Kellermann O; Botti J
Biochimie; 2003; 85(1-2):33-45. PubMed ID: 12765773
[TBL] [Abstract][Full Text] [Related]
14. Prion Infectivity Plateaus and Conversion to Symptomatic Disease Originate from Falling Precursor Levels and Increased Levels of Oligomeric PrPSc Species.
Mays CE; van der Merwe J; Kim C; Haldiman T; McKenzie D; Safar JG; Westaway D
J Virol; 2015 Dec; 89(24):12418-26. PubMed ID: 26423957
[TBL] [Abstract][Full Text] [Related]
15. Mouse prion protein (PrP) segment 100 to 104 regulates conversion of PrP(C) to PrP(Sc) in prion-infected neuroblastoma cells.
Hara H; Okemoto-Nakamura Y; Shinkai-Ouchi F; Hanada K; Yamakawa Y; Hagiwara K
J Virol; 2012 May; 86(10):5626-36. PubMed ID: 22398286
[TBL] [Abstract][Full Text] [Related]
16. Differential solubility of prions is associated in manifold phenotypes.
Kuczius T; Karch H; Groschup MH
Mol Cell Neurosci; 2009 Nov; 42(3):226-33. PubMed ID: 19607920
[TBL] [Abstract][Full Text] [Related]
17. Development of oligomeric prion-protein aggregates in a mouse model of prion disease.
Sasaki K; Minaki H; Iwaki T
J Pathol; 2009 Sep; 219(1):123-30. PubMed ID: 19479969
[TBL] [Abstract][Full Text] [Related]
18. The Size and Stability of Infectious Prion Aggregates Fluctuate Dynamically during Cellular Uptake and Disaggregation.
Shoup D; Priola SA
Biochemistry; 2021 Feb; 60(5):398-411. PubMed ID: 33497187
[TBL] [Abstract][Full Text] [Related]
19. Prion infection: seeded fibrillization or more?
Birkmann E; Riesner D
Prion; 2008; 2(2):67-72. PubMed ID: 19098436
[TBL] [Abstract][Full Text] [Related]
20. The role of rafts in the fibrillization and aggregation of prions.
Pinheiro TJ
Chem Phys Lipids; 2006 Jun; 141(1-2):66-71. PubMed ID: 16647049
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
